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The Prevalence and Odds of Depressive Symptoms
and Clinical Depression in Psoriasis Patients: A
Systematic Review and Meta-Analysis
Emmilia A. Dowlatshahi1, Marlies Wakkee1, Lidia R. Arends2,3,4 and Tamar Nijsten1
The reported prevalence of depression in psoriasis varies substantially. This study aims to determine the
prevalence and odds of depressive symptoms and clinical depression in psoriasis. A systematic literature search
was conducted. Mean questionnaire values and proportions for depressive symptoms and clinical depression
were pooled according to different assessment methods. In controlled studies, standardized mean differences
(SMDs) and odds ratio (OR) compared depression in psoriasis patients with controls using the random-effect
model. The majority of the 98 eligible studies were conducted in tertiary centers without a control group. The
prevalence of depressive symptoms was 28% using questionnaires and the prevalence of clinical depression was
12% using International Classification of Diseases codes, 19% using Diagnostic and Statistical Manual of Mental
Disorders IV, and 9% for antidepressant use. Psoriasis patients had significantly more depressive symptoms (SMD
1.16; 95% confidence interval (CI) 0.67–1.66), and population-based studies showed that they were at least one
and a half times more likely to experience depression (OR 1.57; 95% CI 1.40–1.76) and used more antidepressants
than did controls (OR 4.24, 95% CI 1.53–11.76). More than 10% of psoriasis patients suffer from clinical depression,
and twice as many have depressive symptoms. The high prevalence of these symptoms is likely to be affected by
the tertiary study populations and differential misclassification using questionnaires, where psoriasis-related
symptoms may be detected as depressive symptoms.
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INTRODUCTION
Psoriasis is estimated to affect 3% of the Caucasian population
and is known to have a major impact on patients’ health-
related quality of life (HRQoL; Rapp et al., 1999; De Korte
et al., 2002; Stern et al., 2004). The latter captures patients’
perspectives and may assist in calculating the burden of
disease, in treatment evaluation, and in identifying patients
who are in high need of psychological counseling. Psoriasis
patients often feel impaired by their physical appearance,
leading to stigmatization, avoidance of social interaction, and
isolation. It has been assumed that this altered behavior and
impaired HRQoL may lead to depression, anxiety, stress-
related disorders, and even to suicidal ideation (Gupta and
Gupta, 1998; Sampogna et al., 2007; Schmitt and Ford,
2007b, 2010; Kurd et al., 2010). A study using a structural
equations modeling approach demonstrated the complex
association between psoriatic symptoms, disease severity,
depressive symptoms, and quality of life, showing that a
significant proportion of the variance of depressive
symptoms was explained by HRQoL (Schmitt and Ford,
2007a). However, psoriasis patients may also have other
comorbidities that increase the risk of developing depression
(Langan et al., 2012; Li et al., 2012).
The prevalence of depression in psoriasis varies from 6 to
62%, depending mainly on study design, study population,
sample size, and outcome definition for depression (Richards
et al., 2001; Fortune et al., 2003a; Esposito et al., 2006). Most
studies use validated questionnaires assessing depressive
symptoms. Larger population-based studies using secondary
databases assess depression with International Classification of
Diseases (ICD) codes or measure antidepressant use with
Anatomical Therapeutic Classification codes. Very few
studies define depression on the basis of the 4th edition
of the Diagnostic and Statistical Manual of Mental Disorders
(DSMIV) classification of psychiatric diseases. According to
this classification, major depression is defined as depressed
mood or loss of interest for at least 2 weeks, accompanied by
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five of the following symptoms: weight loss or gain, insomnia
or hypersomnia, psychomotor agitation or retardation, fatigue,
feelings of worthlessness or guilt, diminished concentration,
and recurrent thoughts of death or suicide (American-
Psychiatric-Association, 1994).
We were interested in the extent to which the well-
documented impairment of HRQoL in psoriasis translates into
depressive symptoms (assessed by questionnaires) and ulti-
mately into clinical depression (assessed by antidepressant
use, ICD-codes, and DSMIV). We aimed to provide a pooled
estimate of the prevalence and odds of depressive symptoms
and clinical depression in psoriasis patients.
RESULTS
Study characteristics
The electronic search yielded 1,815 articles, of which 98 were
eligible. Twenty-six studies compared psoriasis patients with
healthy controls (Figure 1).
In the meta-analysis of the 98 studies, data were pooled on
401,703 psoriasis patients. Two studies included 4100,000
patients each (Kurd et al., 2010; Kimball et al., 2011) and
three studies included 420,000 patients each (Dowlatshahi
et al., 2011, 2013; Tsai et al., 2011; Zhang et al., 2011). In the
26 controlled studies, data on 264,568 psoriasis patients and
1,174,612 healthy controls were pooled.
More than one-fourth of studies were conducted in tertiary
centers, of which 17 were restricted to inpatients and 33 to
outpatients (Supplementary Table 1 online). Six studies
assessed depression among members of psoriasis advocacy
groups. Eight very large population-based studies derived their
data from pharmacy, insurance, or administrative databases
(Crown et al., 2004; Kurd et al., 2010; Schmitt and Ford,
2010; Dowlatshahi et al., 2011; Han et al., 2011; Kimball
et al., 2011; Tsai et al., 2011; Zhang et al., 2011).
In 460% of studies, psoriasis was diagnosed by a derma-
tologist. Approximately 40% of studies measured disease
severity using the Psoriasis Area and Severity Index (PASI),
with a mean PASI of 13. The remaining studies either did not
measure the severity, used other measures, or failed to report
the obtained mean PASI values.
The majority of studies assessed depressive symptoms using
questionnaires. Several studies used ICD-codes and only a few
defined depression according to antidepressant use and
DSMIV criteria (Tables 1 and 2). Only 14 studies measured
incident depression—that is, excluding patients with a history
of psychiatric diseases or those taking psychotropic medica-
tion before psoriasis onset.
None of the studies scored the maximum of 10 points on the
modified Newcastle-Ottawa Scale (NOS) for quality assess-
ment. The highest score was 7 points, which was reached by
six studies, whereas the majority of studies scored between
4 and 6 points (n¼67) (Supplementary Table 1 online).
Prevalence of depressive symptoms
Among the 98 studies, the most commonly used questionnaire
was the Hospital Anxiety and Depression Scale (HADS)
followed by the Beck Depression Inventory (BDI) (Table 1).
According to the HADS, the prevalence of depressive
symptoms was 23% using the standard cutoff value of 8, with
a pooled mean value of 5.86 (95% confidence interval (CI)
5.05–6.67). However, the other frequently used instrument,
the BDI, showed that 36% (95% CI 26–46%) of psoriasis
patients were depressed on using the cutoff value of 10 points,
with a pooled mean value of 13.34 (95% CI 11.18–15.51)
(Table 1). The other questionnaires (Hamilton Rating Scale for
Depression (Hamilton RS), Zung Self-Rating Depression Scale
(Zung-SDS), and Center for Epidemiologic Studies Depression
Scale (CESD)) were used only in two or three studies each. The
proportion of depressive symptoms was highest in the studies
using the CESD score (n¼3), with a pooled rate of 55% (95%
CI 31–77%), and was lowest among the studies using the
HADS questionnaire (23%). The forest plot in Figure 3a shows
the prevalence of psoriasis patients with depressive symptoms
for the studies using validated questionnaires (n¼ 33), which
varies a lot, resulting in high heterogeneity (I2¼ 97%,
Po0.001). We notice that there are a few studies reporting
prevalence estimates higher that 50% for depressive symp-
toms. The pooled results estimated that more than a quarter of
the psoriasis patients showed symptoms of depression (28%,
95% CI 22–34%).
Prevalence of clinical depression
The proportion of depressed patients decreased when measur-
ing clinical outcomes: 19% according to the DSMIV and 12%
according to the ICD (Table 1). Antidepressant use was even
lower, with a pooled rate of 9% (95% CI 6–14%) in 10 studies
(Figure 2a). A total of 49% of patients had impaired general
health according to the five studies using the General Health
Questionnaire, which is remarkably higher than the above-
mentioned proportions for depression and depressive symp-
toms (Figure 2a).
Odds of depressive symptoms
Of the 26 controlled studies, 42% used questionnaires. Nine
out of 11 questionnaire-based studies reported mean values
for the used questionnaires, showing that psoriasis patients
were significantly more likely to show depressive symptoms
compared with healthy controls (standardized mean difference
(SMD) 1.16; 95% CI 0.67–1.66; Table 2). In the forest plot
(Figure 3b), the two groups of individuals with depression
confirmed by a psychiatrist from the study by Turel Ermertcan
showed the highest SMDs for depression (3.39, 95% CI 2.50–
4.29 and 4.00, 95% CI 2.99–5.01) (Turel Ermertcan et al.,
2006).The high heterogeneity, with an I2 of 91%, decreased to
82% when excluding these two groups, but remained high.
The majority of the remaining studies had significant SMDs
ranging from 0.47 to 1.97.
According to the HADS and Montgomery Asberg Depres-
sion Rating Scale (MADRS), psoriasis patients were six times
more likely to show depressive symptoms compared with their
healthy peers (odds ratio (OR) 6.06, 95% CI 0.99–37.04;
Figure 2b); however, this result was not significant (P¼0.051).
The difference between psoriasis and controls was greatest
when using the HADS questionnaire (n¼3 studies) with a
pooled OR of 8.00 (95% CI 1.42–45.17). Only one study used
the MADRS questionnaire and its primary objective was to
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compare depressive symptoms in migraine patients with those
in psoriasis patients and healthy controls (Kowacs et al.,
2003). In this study, depressive symptoms were not
significantly elevated in the psoriasis group compared with
the controls (OR 2.13, 95% CI 0.76–3.27; Table 2).
Odds of clinical depression
The likelihood of using antidepressant drugs (n¼ 2 studies)
was four times higher among psoriasis patients (OR 4.24, 95%
CI 1.53–11.76), whereas five studies that used ICD-codes to
assess depression yielded an OR for depression of 1.57 (95%
CI 1.40–1.76). Figure 2b illustrates that the observed OR
for depressive symptoms and clinical depression decreases
according to the following order—depending on the used
instrument—from questionnaires, to antidepressant use, to
ICD-codes.
Meta-regression and subgroup analyses
Heterogeneity between the studies was considerable
(I2490%) when pooling the mean scores of the questionnaires
and proportions of patients with depressive symptoms and
clinical depression. Meta-regression and subgroup analyses
were conducted to determine the possible sources of
heterogeneity.
The rate for depressive symptoms in psoriasis patients
according to questionnaires was independent of mean
age, gender, PASI, and the quality assessment score
(Table 1). No subgroup analysis was conducted on the basis
of study location, because this was already reflected in
the analyses including studies using ICD-codes and anti-
depressants, which were all population-based, versus the
studies using questionnaires, which were mostly based in
tertiary centers.
Embase (1,747)
Medline via OvidSP (490)
Psychlnfo (85)
Cochrane (27)
Pubmed (38)
1,815 Articles after exclusion of duplicates
Titles and abstracts screened
for inclusion criteria
132 Articles
Full text of articles were assessed and articles were
excluded for the following reasons:
- Non-validated depression questionnaire
102 Articles
selected based on full text
98 Studies
included in meta-analysis
98 Studies including
psoriasis patients
26 Studies
including psoriasis
patients and healthy
controls
-  Assessment of depression in dermatological 
 patients and not specifically in psoriasis patients
 (no values for psoriasis patients alone)
- Duplicate studies
- Subjects below the age of 18
Reasons for exclusion from meta-analysis:
-  Missing mean values or percentages for
 depression
- Missing standard deviations available for
 mean depression values
-  Missing confidence intervals reported for
 relative risks
Figure 1. Flowchart of search strategy and study selection.
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The SMD for studies measuring depressive symptoms in
psoriasis compared with controls was neither dependent on
the weighted mean age nor on gender distribution in the
studies. An increase in PASI and NOS score led to a decrease
in the SMD for depressive symptoms (Table 2). We therefore
conducted subgroup analyses for these covariates. Twelve
groups were included in the subgroup analysis of which the
PASI was missing for six groups and was below 10 for the rest;
there was no significant difference in SMD between the two
groups. The six groups with an NOS score below 5 (of which
four groups were from the same study by Turel Ermertcan
et al., 2006) had a higher SMD compared with the groups with
an NOS score above 5 (1.91, 95% CI 1.30 to 2.52 and 0.47,
95% CI –0.09 to 1.03, respectively).
There is possibly some degree of overlap of participants in
studies from two research groups. The studies by Gupta and
Gupta et al., (1988, 1989, 1993, 1994, 1997, 1998), which
were the only to report mean Carroll Rating Scale for
Depression (CRSD), were pooled alone and not included in
the combined analysis. The studies published by the research
group based in Manchester used the HADS, reporting means
or proportion of depressive symptoms (Richards et al., 2001,
2004a, b; Fortune et al., 2002a, b, 2003a, b, 2004, 2005). The
authors could not exclude some degree of overlap of
participants between the studies (CEM Griffiths, personal
communication). Inclusion of all four studies reporting
proportions in the combined analysis resulted in a pooled
proportion of depressive symptoms of 28% (Richards et al.,
2001, 2004b; Fortune et al., 2003a, 2005) and inclusion of
only the largest study (Richards et al., 2001) yielded a similar
proportion of 30% (95% CI 24–37%), suggesting little impact
of the possible overlap of participants.
Publication bias
In the pooled analysis of depressive symptoms in psoriasis (33
studies), there was no publication bias based on the funnel
plot, Eggers regression, or the trim-and-fill method (see
Supplementary Figures online).
With respect to the analyses for questionnaire means in
controlled studies, there was publication bias according to the
Table 1. Depression outcomes in psoriasis patients
Questionnaires reporting mean values for depressive symptoms Number of studies Pooled mean and 95% CI
1
HADS 26 5.86 (5.05–6.67)
BDI 21 13.34 (11.18–15.51)
Hamilton DS 6 6.50 (4.37–8.64)
CRSD 6 13.41 (11.99–14.84)
Zung-SDS 2 31.68 (6.28–57.08)
CESD 2 23.56 (20.39–26.74)
MADRS 1 6.09 (4.17–8.01)
Questionnaires reporting proportion of patients with depressive symptoms Number of studies Pooled rate and 95% CI1
HADS, % patients with a score X8 19 23% (19–27%)
BDI, % patients with a score X10 10 36% (26–46%)
Hamilton DS, % patients with a score 47 2 25% (22–28%)
Zung-SDS, % patients with a score 450 2 37% (29–46%)
CESD, % patients with a score 416 3 55% (31–77%)
All questionnaires
2
33 28% (22–34%)
Clinical outcome measures for depression Number of studies Pooled rate and 95% CI1
ICD 10 12% (8–18%)
DSM IV 4 19% (12–29%)
Antidepressant use 10 9% (6–14%)
MINI interview 2 21% (12–35%)
General health Number of studies Pooled rate and 95% CI1
GHQ, mean value 4 4.93 (3.96–5.89)
GHQ, % patients with a score X2 5 49% (39–58%)
Abbreviations: BDI, Beck Depression Inventory; CES-D, Center for Epidemiologic Studies Depression Scale; CI, confidence interval; CRSD, Carroll Rating Scale
for Depression; DSMIV, Diagnostic and Statistical Manual of Mental Disorders 4th edition; GHQ, General Health Questionnaire; HADS, Hospital Anxiety and
Depression Scale; Hamilton DS, Hamilton Depression Score; ICD, International Classification of Diseases; MADRS, Montgomery Asberg Depression Rating
Scale; MINI, Mini International Neuropsychiatric Interview; NOS, Newcastle-Ottawa Scale; PASI, Psoriasis Area and Severity Index; Zung-SDS, Zung Self-
Rating Depression Scale.
1All estimates were calculated using the method of DerSimonian and Laid and the random-effects model.
2Meta-regression was conducted for this analysis: age: 0.03 ( 0.08 to 0.01); gender:  0.004 ( 0.02 to 0.01); PASI 0.04 (0.008 to 0.09); NOS score:
 0.09 ( 0.28 to 0.10).
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Eggers regression (9.67, 95% CI 4.15–15.20, P¼0.004).
However, only one study was trimmed according to the
trim-and-fill method, yielding an adjusted SMD of 1.37 (95%
CI 0.71–2.03), slightly higher than the unadjusted SMD of
1.16 (95% CI 0.67–1.66) and still significantly elevated for the
psoriasis group.
DISCUSSION
This study shows that psoriasis patients are at least one and a
half times more likely to manifest signs of clinical depression
compared with their healthy peers. More than one-quarter of
psoriasis patients show symptoms of depression and approxi-
mately one-tenth have signs of clinical depression.
These results were independent of the mean age and gender
distribution. The majority of studies included patients with
plaque psoriasis, and studies including only patients with
psoriatic arthritis did not seem to have a higher prevalence of
depression.
Eight studies were population-based and most of them
investigated ICD diagnosis for depression (Kurd et al., 2010;
Schmitt and Ford, 2010; Han et al., 2011; Kimball et al., 2011;
Tsai et al., 2011; Zhang et al., 2011), showing a prevalence of
depression varying from 2 to 10%. These may better reflect
depression in the general psoriasis population compared with
most of the other studies conducted in tertiary centers using
questionnaires, which assess only depressive symptoms and
are likely to overestimate the prevalence of depression
(Pignone et al., 2002). Questionnaires are case-finding
instruments and may capture somatic symptoms that are not
necessarily indicative of clinical depression.
Patients from the studies investigating antidepressant use
represented the entire span of the psoriasis population:
patients from psoriasis associations, patients recruited through
internet advertisements, inpatients, outpatients, and patients
registered in large pharmacy and health-care databases. The
pooled proportion of 9% therefore reflects antidepressant use
in the broad psoriasis population, which is in line with the
depression rates obtained using ICD-codes.
The pooled analysis of studies using the DSMIV criteria, the
gold standard for the diagnosis of depression, yielded high
rates for depression. This could have several explanations: it
could be due to the low number of available studies (n¼4),
the tertiary study setting, the highly selective psoriasis popula-
tion with moderate to severe disease, or the fact that patients
with an elevated questionnaire score were subjected to the
DSMIV criteria (Sharma et al., 2001; Biljan et al., 2009; Chan
et al., 2009; Golpour et al., 2012). Another explanation could
be the discrepancies between ICD-10 and DSMIV related to
mental disorders (Andrews et al., 1999). A recent study
showed that the ICD-10 was more sensitive to the mild
range of depressive symptoms, whereas the DSMIV was
more sensitive to the moderate to severe range (Saito et al.,
2010). In the case of attention deficit/hyperactivity disorder,
the prevalence was more than twice as high according to the
DSMIV criteria (Dopfner et al., 2008). Finally, diagnosing
patients using the DSMIV is time consuming and necessitates a
psychiatrist or a psychologist, possibly explaining why it is not
commonly used in a dermatology setting.
Chronic diseases affect the psychological health of patients,
and higher levels of psychosocial disability decrease treatment
adherence, resulting in treatment dissatisfaction, which may
also contribute to depression (Schmitt and Ford, 2007b).
Depression has been proven to be a common comorbidity
in patients with chronic diseases such as diabetes, rheumatoid
Table 2. Depression outcomes in psoriasis patients compared with healthy controls
Questionnaires reporting mean values for depressive symptoms Number of studies Pooled SMD and 95% CI1
BDI 4 0.86 (0.36–1.35)
HADS 2 0.48 (0.19–0.77)
Hamilton DS 2 2.08 (0.83–3.34)
MADRS 1  0.06 ( 0.45–0.33)
All questionnaires
2
9 1.16 (0.67–1.66)
Questionnaires reporting proportion of patients with depressive symptoms Number of studies Pooled OR and 95% CI1
HADS, % patients with a score X8 3 8.00 (1.42–45.17)
MADRS, % patients with a score 410 1 2.13 (0.76–3.27)
All questionnaires 4 6.06 (0.99–37.04)
Clinical outcome measures for depression Number of studies Pooled OR and 95% CI1
Antidepressant use, % psoriasis compared with controls 2 4.24 (1.53–11.76)
ICD, % psoriasis compared with controls 5 1.57 (1.40–1.76)
General health Number of studies Pooled OR and 95% CI1
GHQ, % patients with a score X3 1 0.90 ( 0.10–1.79)
Abbreviations: BDI, Beck Depression Inventory; CI, confidence interval; GHQ, General Health Questionnaire; HADS, Hospital Anxiety and Depression Scale;
Hamilton DS, Hamilton Depression Score; ICD, International Classification of Diseases; MADRS, Montgomery Asberg Depression Rating Scale; NOS,
Newcastle-Ottawa Scale; PASI, Psoriasis Area and Severity Index; SMD, standardized mean difference.
1Estimates were calculated using the method of DerSimonian and Laid and the random-effects model.
2Meta-regression was conducted for this analysis: age: –0.03 (0.16 to 0.09); gender: 0.0008 ( 0.29 to 2.67); PASI  0.72 ( 1.39 to ( 0.05)); NOS score
–0.51 ( 0.88 to ( 0.14)).
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arthritis, and heart failure, with comparable differences in
proportions of depressive symptoms and clinical depression
(Anderson et al., 2004; Dickens et al., 2002; Rutledge et al.,
2006; Nouwen et al., 2010; Palmer et al., 2013). It is
challenging to conduct a head-to-head comparison of the
prevalence of depression in patients with different chronic
conditions because the studies do not always use the same
case definition for depression.
We observe that the differences between the instruments in
the proportion of subjects assessed as having depression were
much larger in patients with psoriasis. In the controls, there
was only a modest difference between the proportion of
subjects with depressive symptoms according to the HADS
score and subjects with clinical depression according to
antidepressant use and ICD-code. A possible explanation
could be that the psychometric properties of questionnaires
assessing depressive symptoms have been extensively studied,
but not in a population with skin diseases. Therefore, psoriasis-
related symptoms and complaints may be falsely detected by
the questionnaires as being depressive symptoms, resulting in
differential misclassification and an overestimation of the
prevalence of depressive symptoms in psoriasis patients
compared with healthy controls. Furthermore, studies using
questionnaires predominantly include psoriasis patients from
tertiary centers, with severe disease, who may therefore also
have more symptoms of depression.
A study by Schmitt and Ford (2007a) showed a high
convergent validity of the CESD in psoriasis patients,
hypothesizing that HRQoL impairment leads to depressive
symptoms. In this study, a significant proportion of the
variance of depressive symptoms was explained by HRQoL.
The fact that QoL indexes correlate with measures of
psychiatric symptoms (McHorney et al., 1993) was also
confirmed in a cluster analysis by Sampogna et al. (2004) in
psoriasis patients, showing two distinct groups: one based on
clinical severity measurements and another formed by QoL
and psychological indexes.
Strengths and limitations
This is to date the largest study to systematically summarize
the available data on depression in psoriasis. The broad
inclusion criteria for depression instruments enable the study
of these different tools and their effect on the prevalence and
odds of depression. We chose to focus on depression as
outcome. Nevertheless, antidepressant use may not be neces-
sarily indicative of underlying depressive disease, as the
frequency of off-label use in medically ill patients is quite
high; moreover, antidepressant use could reflect other mental
disorders as well. Several studies could not be included
because they did not use one of the validated instruments,
possibly leading to reporting bias. However, there did not
seem to be considerable publication bias, neither for con-
trolled nor for uncontrolled studies.
There were a large number of uncontrolled studies
in this meta-analysis, including a very specific psoriasis
population, possibly resulting in selection bias. Further-
more, the questionnaires may have been administered in a
specific way to individuals from these studies, leading to
information bias.
Most of the included questionnaires were primarily
designed to assess the intensity of depression in psychiatri-
cally diagnosed patients (BDI and Hamilton RS) and were
70
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Figure 2. Pooled prevalence and OR of depression according to the
assessment method. (a) Questionnaires include Hospital Anxiety and
Depression Scale, Hamilton Depression Score, Beck Depression Inventory, Zung
Self-Rating Depression Scale, and Center for Epidemiologic Studies Depression
Scale (see Table 1). ‘‘n’’ Represents the number of studies per assessment
method. (b) Questionnaires include Hospital Anxiety and Depression Scale and
Montgomery Asberg Depression Rating Scale (see Table 2). ‘‘n’’ Represents the
number of studies per assessment method. CI, confidence interval; DSMIV,
Diagnostic and Statistical Manual of Mental Disorders 4th edition; GHQ,
General Health Questionnaire; ICD, International Classification of Diseases;
MINI, Mini International Neuropsychiatric Interview; OR, odds ratio.
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Study name Statistics for each study
Proportion of depressive symptoms in psoriasis patients
Standardized mean difference for depressive symptoms in psoriasis patients compared with healthy controls
Event rate and 95% CI
Event
Rate
McAleer 2011 0.07 0.04 0.13 0.00
Paloma 2011 0.52 0.43 0.61 0.67
Richards 2004 0.12 0.05 0.25 0.00
Kirby 2008 0.22 0.14 0.32 0.00
Hill 2002 0.27 0.19 0.37 0.00
Fortune 2003 0.06 0.03 0.12 0.00
Fortune 2005 0.16 0.10 0.25 0.00
Yang 2005 0.10 0.05 0.18 0.00
Richards 2001 0.10 0.06 0.17 0.00
Freire 2011 0.12 0.09 0.15 0.00
Consoli 2006 0.26 0.18 0.36 0.00
Mizara 2012 0.25 0.15 0.38 0.00
Scharloo 2000 0.29 0.20 0.41 0.00
Langley 2010 placebo 0.31 0.27 0.36 0.00
Langley 2010 Ust45 0.24 0.20 0.29 0.00
Langley 2010 Ust90 0.25 0.21 0.29 0.00
Dauden 2009 ETN paused 0.37 0.32 0.42 0.00
Dauden 2009 ETN continuous 0.30 0.26 0.35 0.00
Schneider 2006 0.21 0.14 0.31 0.00
Tyring 2006 placebo BDI 0.35 0.30 0.41 0.00
Tyring 2006 etanercept BDI 0.34 0.29 0.39 0.00
Ghajarzadeh 2011 0.67 0.57 0.75 0.00
Devrimci-Ozguven 2000 0.44 0.31 0.58 0.40
Reich 2010 0.21 0.14 0.30 0.00
Mercan 2008 0.42 0.24 0.62 0.42
Golpour 2012 0.67 0.57 0.75 0.00
Zamirska 2008 with vulvar itch 0.39 0.25 0.54 0.16
Zamirska 2008 no vulvar itch 0.19 0.11 0.32 0.00
Akay 2002 0.58 0.44 0.71 0.26
Taner 2007 0.04 0.02 0.11 0.00
Kanikowska 2009 0.22 0.15 0.30 0.00
Mossner 2009 HamDS 0.20 0.14 0.28 0.00
Tyring 2006 placebo 0.26 0.21 0.31 0.00
Tyring 2006 etanercept 0.25 0.21 0.30 0.00
Menter 2010 placebo Zung 0.37 0.25 0.51 0.06
Menter 2010 adalimumab 0.32 0.20 0.47 0.02
Colonna 2004 0.45 0.28 0.62 0.56
Esposito 2006 overall CESD 0.62 0.60 0.64 0.00
Schmitt 2007 0.80 0.75 0.85 0.00
Kulkarni 2004 0.19 0.11 0.30 0.00
0.28 0.22 0.34 0.00
–1.00 –0.50 0.00 0.50 1.00
Study name Statistics for each study Std diff in means and 95% CI
Std diff
in means
Lee 2010 0.74 0.21 0.34 1.15 0.00
Guler 2009 0.20 0.23 –0.25 0.65 0.38 
Ak 2011 0.96 0.20 0.57 1.34 0.00
Mercan 2008 1.63 0.31 1.02 2.23 0.00
Smith 2002 0.49 0.24 0.02 0.96 0.04
Richards 2004 0.47 0.19 0.10 0.84 0.01
Chaudhury 1998 1.97 0.31 1.35 2.59 0.00
Turel Ermertcan 2006 females no dep 1.00 0.32 0.38 1.62 0.00
Turel Ermertcan 2006 males no dep 0.29 0.28 –0.25 0.83 0.30
Turel Ermertcan 2006 female with dep 3.39 0.46 2.50 4.29 0.00
Turel Ermertcan 2006 males with dep 4.00 0.51 2.99 5.01 0.00
Kowacs 2003 –0.06 0.20 –0.45 0.33 0.76
 1.16 0.25 0.67 1.66 0.00
–5.00 –2.50 0.00 2.50 5.00
P-value
Upper
limit
Lower
limit
Standard
error
Lower
limit
Upper
limit P-value
Figure 3. Forest plots of studies using questionnaires reporting proportions or mean values for depressive symptoms. (a) The mentioned studies and groups used
the Hospital Anxiety and Depression Scale, Hamilton Depression Score, Beck Depression Inventory (BDI), Zung Self-Rating Depression Scale, and Center for
Epidemiologic Studies Depression Scale (CESD) to measure depressive symptoms. (b) The mentioned studies used the Beck Depression Inventory, Hamilton
Depression Score, Hospital Anxiety and Depression Scale, and Montgomery Asberg Depression Rating Scale to measure depressive symptoms. CI, confidence
interval.
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subsequently used to detect depressive symptoms in normal
populations. These instruments were validated for non-der-
matological diseases and no validation studies have been
conducted in psoriasis. The HADS is the most commonly
used depression-screening instrument in psoriasis because of
its feasibility; however, a review noted that the BDI, CESD,
and the Zung-SDS were among the most thoroughly eval-
uated instruments in primary care (Williams et al., 2002).
Only four studies used the DSMIV criteria, and therefore no
distinction could be made in the studies between patients
with major or minor depression and dysthymia. Only two
studies used a questionnaire followed by a clinical interview
(Sharma et al., 2001; Golpour et al., 2012), in accordance
with the case-finding approach to diagnosing depression
(Pignone et al., 2002).
The appraisal of the eligible studies showed that only a
small percentage scored high points for the NOS score. One
point was allocated to the studies with a healthy control
group, representative of the average community. Therefore,
470% of all studies, without a control group or with a
selected control group (hospital controls or controls with other
dermatological conditions), did not get a point for this item.
Determining the prevalence of depression was not always
the primary objective of the studies included; several studies
were primarily interested in comparing depression in psoriasis
patients with depression in patients with other skin conditions,
whereas others focused on the effect of psoriasis therapy on
depressive symptoms.
Data from different studies were pooled despite the high
degree of heterogeneity, which is partly a result of the varying
prevalence and odds of depression according to studies. This,
together with the fact that very few studies were available for
some of the outcomes, could also explain the large confidence
intervals. Meta-regression and subgroup analyses were con-
ducted to attempt and explain this heterogeneity.
The results of this study, particularly those of the ques-
tionnaires, may not entirely be extrapolated to the general
psoriasis population. The prevalence of depressive symptoms
was mainly determined in convenient samples of psoriasis
patients from tertiary care populations. On the other hand, the
prevalence obtained from population-based studies could be
generalized to the psoriasis population.
Conclusions
In addition to the impact on HRQoL, psoriasis patients
manifest more signs of depression compared with healthy
controls. The prevalence is highest for depressive symptoms in
patients consulting tertiary centers. This could be because of
misclassification of psoriasis-related symptoms as being
depressive symptoms when using questionnaires. Approxi-
mately 10% of psoriasis patients from the general population
suffer from clinical depression.
Although we did not identify clear risk factors associated
with psychological distress, we recommend administering
an HRQoL tool or a depression questionnaire to patients
who seem to be severely affected by their psoriasis. In
patients suspected of depression, physicians should actively
ask for signs of clinical depression, as elaborated in the
DSMIV classification, and if necessary refer them to a
psychiatrist.
MATERIALS AND METHODS
Types of studies
No restrictions were made as to the type of study (experimental or
observational), publication date, or language.
Types of participants
Studies conducted in adults aged 18 years and older were included.
Psoriasis patients were defined as those with a confirmed diagnosis of
psoriasis by a physician (dermatologist, rheumatologist, general
practitioner, or other health-care provider), a self-report of a physi-
cian’s diagnosis for psoriasis, or according to a diagnostic code
(ICD9: 696.0-1/ICD10: L40.0-9, or OXMIS code). No restriction was
made as to the type of psoriasis, but a distinction was made as to
whether studies included patients with cutaneous plaque psoriasis,
psoriatic arthritis, or other types.
Types of outcome measures
Depression was defined using different methods: (1) diagnosis by a
psychiatrist, psychologist, general practitioner, or other health-care
provider, (2) DSMIV criteria, (3) self-report of a physician’s diagnosis
of depression, (4) ICD-codes (ICD-9-CM 296.2-3, 298.0, 300.4,
309.1, 311, ICD10: F32.0-9 and F33.0-9), (5) Mini International
Neuropsychiatric Interview (Sheehan et al., 1998), (6) antidepressant
use using Anatomical Therapeutic Classification codes or self-report,
and (7) validated questionnaires assessing depressive symptoms such
as the BDI (Beck et al., 1961, 1988), CESD (Beekman et al., 1997),
HADS (Zigmond and Snaith, 1983; Bjelland et al., 2002), Hamilton
DS (Hamilton, 1960), CRSD (Carroll et al., 1981; Smouse et al.,
1981), Zung-SDS (Zung, 1965; Gilbody et al., 2005), and MADRS
(Montgomery and Asberg, 1979). The General Health Questionnaire
measured a patient’s ‘‘general health’’ (Goldberg, 1986; Gilbody
et al., 2005). These questionnaires and their cutoff values are
described in the Supplementary Table 2 online.
Search strategy
The search was conducted by a medical librarian in Embase, Med-
line, PubMed, PsychInfo, and the Cochrane Database, from inception
to August 2012 (Supplementary Material online).
Study selection and data extraction
The titles and abstracts were screened and articles were selected on
the basis of the inclusion and exclusion criteria. Data were extracted
using a standardized form (Supplementary Table 1 online). Baseline
values for proportions or mean values according to questionnaires,
and the proportion of patients with a diagnostic code for depression
or antidepressant use, were registered. Studies in which outcome
values were reported separately for subgroups were also included
(Supplementary Table 1 online). When several studies reported results
from the same population, the study with the most complete data was
included in the meta-analysis. Participants from the same studies
were only included once per combined analysis. However, in one
study by Turel Ermertcan et al, the results of psoriasis patients were
split into four groups and there were only two control groups. We
therefore included information on the control group twice in order to
be able to calculate an SMD for the four psoriasis groups.
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The quality of the articles was rated using an adapted version of the
NOS (range 0–10; Wells et al, 2012; for the score sheet, see
Supplementary Methods online).
These steps were conducted independently by EAD and FSvL or
EAD and MW. Differences were resolved and consensus was reached
through discussion.
Statistical analysis
In controlled and uncontrolled studies, pooled mean values and the
prevalence of psoriasis patients with depressive symptoms according
to the questionnaires were calculated. Pooled prevalence of clinical
depression in psoriasis was calculated according to antidepressant
use, ICD, and DSMIV.
In controlled studies, depressive symptoms were compared
between psoriasis patients and controls by calculating the difference
in mean questionnaire values, obtaining an SMD and 95% CI. OR
and 95% CI for depressive symptoms and clinical depression between
psoriasis patients and controls were obtained according to question-
naires, antidepressant use, ICD, and the DSMIV.
The analyses were performed using a random-effects model
according to the method of DerSimonian and Laird (1986), taking
into account within-study and between-study variance.
Heterogeneity between studies was quantified using I2 statistics
(Higgins and Thompson, 2002). Publication bias was assessed
graphically with funnel plots and statistically with Egger’s regression
(Egger et al., 1997). The trim-and-fill method provided an estimate of
the number of missing studies and of the pooled effect size if these
studies had been included.
Meta-regression and subgroup analyses
Sources of heterogeneity between studies were explored by perform-
ing meta-regression for age, gender, PASI, and NOS score (deter-
mined a priori). Another method used to address the heterogeneous
data was to conduct subgroup analyses. In this study, the primary
subgroup analysis consisted of the distinction between the different
methods of assessment for depression. In addition, subgroup analyses
were performed for variables that were significant in the meta-
regression.
This study was conducted and reported in accordance with the
PRISMA guidelines for reporting systematic reviews and meta-ana-
lyses (Liberati et al., 2009).
All statistical analyses were performed using Comprehensive Meta-
Analysis Version 2.2 (Biostat, Englewood, NJ).
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